Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

Background We conducted the first trial of neoadjuvant PD-1 blockade in resectable non-small cell lung cancer (NSCLC), finding nivolumab monotherapy to be safe and feasible with an encouraging rate of pathologic response. Building on these results, and promising data for nivolumab plus ipilimumab (a...

Full description

Bibliographic Details
Main Authors: Drew M Pardoll, Julie R Brahmer, Patrick M Forde, Jarushka Naidoo, David Jones, Taha Merghoub, Suzanne Topalian, Gary Rosner, Valsamo Anagnostou, Hok Yee Chan, Franco Verde, Daphne Wang, Matthew D Hellmann, Victor E Velculescu, James R White, Tricia R Cottrell, Joshua E Reuss, Stephen Broderick, Kellie N Smith, Marianna Zahurak, Mara Lanis, Joseph C Murray, Caroline McCarthy, Richard Battafarano, Errol Bush, Malcolm Brock, Jinny Ha, Janis Taube, Peter Illei, Ben Levy, Jamie E Chaft
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001282.full

Internet

https://jitc.bmj.com/content/8/2/e001282.full

Similar Items